Author’s response to reviews

Title: Glutamate metabotropic receptor 4 (GRM4) inhibits cell proliferation, migration and invasion in breast cancer and is regulated by miR-328-3P and miR-370-3P

Authors:

Bin Xiao (xiaobin2518@163.com)
Daxiang Chen (1101072690@qq.com)
Quan Zhou (springzhou@yeah.net)
Jianfeng Hang (hyhy160@163.com)
Weiyun Zhang (1261349825@qq.com)
Zhenzhan Kuang (864156363@qq.com)
Zhaohui Sun (zhaohui3@126.com)
Linhai Li (mature303@126.com)

Version: 3 Date: 19 Aug 2019

Author’s response to reviews:

Editor Comments:

1 - We note that the current submission contains textual overlap with other previously published works. Please re-write these sentences and phrases in your own words to ensure no overlap. If there is overlap in the Methods section, please ensure that you summarize the methods and cite the source.
Response: We have assessed the overlap and re-written these parts in my own words.

2 - Please include a Keywords section to follow the Abstract. Three to ten keywords representing the main content of the article should be included.
Response: We have added five keywords following the Abstract.

3 - If human cell lines are used, authors are strongly encouraged to include the following information in their manuscript:
• The source of the cell line, including when and from where it was obtained
• Whether the cell line has recently been authenticated and by what method
• Whether the cell line has recently been tested for mycoplasma contamination
Further information is available from the International Cell Line Authentication Committee (ICLAC). We recommend that authors check the NCBI database for misidentification and contamination of human cell lines. Please include the sources of all cell lines and their catalogue numbers.
Response: We have included these information in Methods-Cell lines and cell culture section as you required.

4 - Please confirm whether any of the cell lines required ethics approval for their use and include a statement in the Ethics approval and consent to participate section in the Declarations.
Response: None of the cell lines required ethics approval for their use in this study. We have included this statement in the Ethics approval and consent section.

5 - Please revise your ‘Declaration’ section to be in the following order with these headings:
   Declarations
   - Ethics approval and consent to participate
   - Consent for publication
   - Availability of data and materials
   - Competing interests
   - Funding
   - Authors' Contributions
   - Acknowledgements
   - Authors' Information (optional)
Response: We have revised “Declaration” section in the order that you request.

6 - In the Funding section of the Declarations please indicate the role of the funding body in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript. If no specific funding was received for this study, please clearly indicate this in the Funding section.
Response: No specific funding was received for this study. We have indicated this in the Funding section.

7 - Please clarify why YL is included in the Authors' contributions section when no longer on the manuscript as author.
Response: This is a mistake. According to his personal willingness, YL (Yang Liao) is included in the Acknowledgements section and no longer as an author.

8 - At this stage, please upload your manuscript as a single, final, clean version that does not contain any tracked changes, comments, highlights, strikethroughs or text in different colours. All relevant tables/figures/additional files should also be clean versions. Figures (and additional files) should remain uploaded as separate files.
Response: We have uploaded all the files according to your requirements.

Reviewer reports:
Francesca Peruzzi (Reviewer 1): Please correct the name of the miRNAs as -3p or -5p instead of -3P and -5P
Response: We have corrected the name of the miRNAs in the Figures and main text as you request.